MS
63 programs · 62 companies
Programs
63
Companies
62
Trials
52
MOAs
41
CDK4/6iVEGFiKRASG12DiBCMA ADCAuroraAiJAK1/2iSGLT2iBTKiCl18.2CAR-T BCMA
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-1969 | Approved | BET | ||
| Doxasotorasib | Phase 2 | CD38 | ||
| Ivotuximab | NDA/BLA | GIP-R | ||
| Olpatinib | Preclinical | PD-L1 | ||
| DSN-791 | NDA/BLA | Aβ | ||
| VRT-9481 | Phase 1/2 | Menin | ||
| MRN-8225 | Preclinical | TNFα | ||
| BMR-8377 | Phase 1/2 | PCSK9 | ||
| HAL-9635 | Phase 2/3 | EZH2 | ||
| JAZ-8729 | Phase 2/3 | FcRn | ||
| 369-789 | Phase 3 | PI3Kα | ||
| ILM-5680 | Phase 2 | BET | ||
| Terazumab | Phase 3 | AHR | ||
| Zanumavacamten | Phase 2 | FLT3 | ||
| Polaglumide | Phase 3 | TYK2 | ||
| GLP-3342 | Phase 1/2 | PLK4 | ||
| CSL-4459 | NDA/BLA | KRASG12D | ||
| 450-8195 | NDA/BLA | TROP-2 | ||
| Capivorutinib | Phase 2 | IL-17A | ||
| ISO-9327 | Phase 1 | KRASG12C | ||
| Mirinesiran | Phase 3 | DLL3 | ||
| AGE-4274 | Phase 1 | FcRn | ||
| ALG-2734 | Approved | Tau | ||
| Olparelsin | Preclinical | FcRn | ||
| Voxacapivasertib | Phase 1/2 | BET | ||
| Polacagene | Preclinical | SMN2 | ||
| GLY-5612 | Phase 3 | FXIa | ||
| CIR-5071 | Phase 2 | CGRP | ||
| ELO-7470 | Preclinical | CDK2 | ||
| Tixacagene | Preclinical | SMN2 | ||
| Zenomavacamten | Phase 3 | CFTR | ||
| Liraratamab | Approved | FcRn | ||
| Lisosertib | Phase 1 | CD3 | ||
| Nidatuximab | Preclinical | MALT1 | ||
| TRE-8359 | Preclinical | SMN2 | ||
| GEN-IIT-455 | Phase 2/3 | GLP-1R | ||
| Olpacagene | NDA/BLA | CD20 | ||
| 174-8981 | Phase 2 | Aβ | ||
| LAU-2489 | Phase 2 | B7-H3 | ||
| IPH-2316 | Preclinical | VEGF | ||
| MRK-876 | Preclinical | KRASG12D | ||
| Datomavacamten | Preclinical | CD19 | ||
| SUP-4355 | Phase 2 | IL-17A | ||
| DAR-2860 | Phase 1 | GLP-1R | ||
| Doxazumab | Phase 1/2 | FGFR | ||
| Lisonesiran | Phase 2 | PRMT5 | ||
| MAG-3823 | Phase 1 | WEE1 | ||
| Ribotenlimab | NDA/BLA | AuroraA | ||
| DIV-5162 | Preclinical | USP1 | ||
| SIA-643 | Phase 1 | BCL-2 | ||
| Gelifutibatinib | Approved | PARP | ||
| RIK-IIT-829 | Phase 3 | CFTR | ||
| NAT-IIT-326 | Phase 1/2 | PARP | ||
| HOS-IIT-835 | Phase 3 | AuroraA | ||
| INT-6808 | Approved | EZH2 | ||
| Elratuximab | NDA/BLA | PI3Kα | ||
| Teraosocimab | Approved | C5 | ||
| STA-6220 | Phase 1 | KRASG12C | ||
| LEO-5676 | Phase 2/3 | PCSK9 | ||
| PAH-7465 | Phase 2 | CD3 | ||
| Sovarelsin | Phase 1/2 | CD123 | ||
| Sovalemzoparlimab | Phase 3 | GPRC5D | ||
| 453-4974 | NDA/BLA | PLK4 |
Trials (52)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT03478696 | Ivotuximab | NDA/BLA | Recruiting |
| NCT05363043 | Olpatinib | Preclinical | Recruiting |
| NCT03957704 | VRT-9481 | Phase 1/2 | Completed |
| NCT04296448 | MRN-8225 | Preclinical | Recruiting |
| NCT08907623 | HAL-9635 | Phase 2/3 | Not yet recr... |
| NCT03412600 | 369-789 | Phase 3 | Not yet recr... |
| NCT03908408 | 369-789 | Phase 3 | Terminated |
| NCT08642385 | ILM-5680 | Phase 2 | Active |
| NCT04537324 | Terazumab | Phase 3 | Active |
| NCT07035347 | Zanumavacamten | Phase 2 | Terminated |
| NCT08641505 | Polaglumide | Phase 3 | Terminated |
| NCT08662967 | GLP-3342 | Phase 1/2 | Active |
| NCT05010370 | GLP-3342 | Phase 1/2 | Terminated |
| NCT05019951 | CSL-4459 | NDA/BLA | Completed |
| NCT06774147 | 450-8195 | NDA/BLA | Completed |
| NCT08761665 | ISO-9327 | Phase 1 | Not yet recr... |
| NCT06258536 | Mirinesiran | Phase 3 | Terminated |
| NCT05195042 | Mirinesiran | Phase 3 | Recruiting |
| NCT04026435 | Mirinesiran | Phase 3 | Terminated |
| NCT03364656 | Mirinesiran | Phase 3 | Recruiting |